# Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease

> **NCT00543374** · PHASE3 · COMPLETED · sponsor: **Mesoblast, Inc.** · enrollment: 98 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** PROCHYMAL adult human mesenchymal stem cells

## Key facts

- **NCT ID:** NCT00543374
- **Lead sponsor:** Mesoblast, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-17
- **Primary completion:** 2009-07
- **Final completion:** 2011-04-28
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543374, "Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00543374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*